


# ADVANCING THE LUNG CANCER TREATMENT LANDSCAPE



## NOVEL TARGETS FOR IMPROVED PATIENT CARE

Sunday 11 September 2022  
13.00–14.30 CEST

Grenoble Auditorium Hall 7, Level 7.3  
Paris Expo Porte de Versailles  
Paris, France



Add a reminder  
to your calendar


Dear Sir/Madam,

We are delighted to invite you to the Amgen-sponsored symposium to be held at the European Society for Medical Oncology (ESMO) 2022 congress, entitled: '**Advancing the lung cancer treatment landscape: novel targets for improved patient care**'.

**Click the video below** to watch the symposium Chair, Professor Fabrice Barlesi, introduce the Faculty and the topics to be discussed in this 90-minute session exploring the evolving field of lung cancer treatment.

The symposium will conclude with an engaging 20-minute panel discussion with an audience Q&A.

**ADVANCING**  
THE LUNG CANCER  
TREATMENT LANDSCAPE:  
**NOVEL TARGETS  
FOR IMPROVED  
PATIENT CARE**



PLAY



**Sunday 11 September 2022**

**13.00-14.30 CEST**

7.3 G- Grenoble Auditorium Hall 7, Level 7.3

Paris Expo Porte de Versailles

Paris, France

SC-ELMAC-CP-00148

**AMGEN**  
Oncology

## PROGRAMME

- Welcome and introduction  
**Fabrice Barlesi, France**
- Non-squamous versus squamous NSCLC: actionable and emerging targets  
**Jürgen Wolf, Germany**
- Towards a new era of biomarker-driven therapy in SCLC  
**Noemi Reguart, Spain**
- Expanding treatment opportunities in SCLC: targeting DLL3  
**Stéphane Champiat, France**
- Panel discussion and Q&A  
**All**

Please come and join us in **7.3.G- Grenoble Auditorium Hall 7, Level 7.3 at 13.00 CEST** for this engaging and informative session.

Best regards,

Global Medical Team, Oncology

Disclaimer: This message and any attachments are solely for the intended recipient and may contain confidential or privileged information. If you are not the intended recipient, any disclosure, copying, use, or distribution of the information included in this message and any attachments is prohibited.

If you have received this communication in error, please notify us by replying to this email and permanently delete this message and any attachments.  
Thank you.

[Unsubscribe here](#)

**AMGEN**<sup>®</sup>

Oncology

SC-ELMAC-CP-00148  
Amgen Europe GmbH  
6343 Rotkreuz, Switzerland  
Date of preparation: August 2022  
www.amgen.com © 2022 Amgen Inc.  
All rights reserved.